1. Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia
- Author
-
Nauman Butt, John T. Reilly, Adam J. Mead, Eibhlin Conneally, Anthony R. Green, Richard Murrin, Mary Frances McMullin, Claire N. Harrison, Deepti Radia, Mark Drummond, Peter J. Campbell, and Nicholas C.P. Cross
- Subjects
medicine.medical_specialty ,Diagnosis, Differential ,Internal medicine ,Correspondence ,medicine ,Humans ,In patient ,Myelofibrosis ,Hematology ,medicine.diagnostic_test ,Thrombocytosis ,Platelet Count ,business.industry ,Bone Marrow Examination ,medicine.disease ,Dermatology ,Bone marrow examination ,Mutation ,Practice Guidelines as Topic ,Immunology ,Differential diagnosis ,business ,Megakaryocytes ,Algorithms ,Calreticulin Gene ,Thrombocythemia, Essential - Abstract
The diagnosis of the myeloproliferative neoplasms (MPN)‒ essential thrombocythaemia (ET) and primary myelofibrosis (PMF) ‒ in patients lacking a molecular marker is challenging. Recently, mutations in exon 9 of the calreticulin gene (CALR) have been described in around one-third of ET and MF patients (Klampfl et al, 2013a; Nangalia et al, 2013). Notably, these mutations are almost always seen in JAK2 V617F-negative and MPL-non-mutated patients and account for the majority of these cases. Such is the prevalence of these mutations we suggest that they are added to the British Committee for Standards in Haematology criteria for the diagnosis of ET and also PMF (Harrison et al, 2010; Reilly et al, 2012) (evidence grade 1A). The modified diagnostic criteria and algorithms are shown in
- Published
- 2016
- Full Text
- View/download PDF